Nan Fung Group Holdings Ltd

Q1 2022 13F Combination Report, Stock Holdings

Signature - Title
Tang Chun Wai Nelson - Director
Location
Kai Tak, Hong Kong
Holdings as of
March 31, 2022
Value $
$211M
Num holdings
45
Date filed
5/13/2022, 04:23 PM
Form type
13F-HR
Description
A portion of the US holdings for this investor are reported in this report and a portion are reported by other reporting manager(s). Top holdings included ILMN, HRMY, KRTX, EAR, and SLGC.
Previous filing
Q4 2021 - Feb 14, 2022
Next filing
Q2 2022 - Aug 12, 2022
SEC
View on sec.gov
Filing 2022 Q1 compared to 2021 Q4 by default.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.

Person Signing this Report on Behalf of Reporting Manager:

Name Title City, State Date
Tang Chun Wai Nelson Director Central, Hong Kong 5/13/2022

List of Other Managers Reporting for Nan Fung Group Holdings Ltd:

Name Holdings Value Location File Number
Pivotal bioVenture Partners Fund I U.G.P. Ltd San Francisco, CA 028-20631
Pivotal bioVenture Partners Investment Advisor LLC $124M San Francisco, CA 028-20630

Other Included Managers (2):

Num Name Location File Number
1 Pivotal bioVenture Partners Investment Advisor LLC San Francisco, CA 028-20630
2 Pivotal bioVenture Partners Fund I U.G.P. Ltd San Francisco, CA 028-20631